Product Description
IPI-493 is a potent inhibitor of heat shock protein 90 (Hsp90) and is orally bioavailable via a novel formulation. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00724425)
Mechanisms of Action: HSP90 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Oncology Unspecified|Chronic Myeloid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IPI-493-01 | P1 |
Terminated |
Oncology Unspecified |
2011-07-01 |
|
| IPI-493-02 | P1 |
Terminated |
Chronic Myeloid Leukemia |
2011-07-01 |